Transderm-V
Texto original en francés.
Producto de salud natural autorizado en Canadá
- Titular
- Sandoz Canada Inc.
- NPN o DIN-HM
- 80024336
- Estado
- Licencia no activa
- Fecha de licencia
- 22 de marzo de 2011
- Fecha de revisión
- 28 de mayo de 2019
- Forma
- Timbre transdermique
- Vía de administración
- Transdermique
- Tipo de solicitud
- Non traditionnelle
El análisis de dosis orales no se aplica sin una vía exclusivamente oral establecida.
Composición
Composición medicinal no indicada.
Ingredientes no medicinales
Light mineral oil, Polyisobutylene 1200000, Polyisobutylene 35000
Dosis recomendadas en Canadá
| Población | Edad | Cantidad por toma | Frecuencia |
|---|---|---|---|
| Adultes | Non précisée | 1 patch | Non précisée |
Usos autorizados en Canadá
Prevention of symptoms of motion sickness such as nausea and vomiting. To help in the prevention of nausea and vomiting in postoperative patients.
Texto original en inglés.
Un uso autorizado en Canadá no es una declaración de propiedades saludables autorizada en la Unión Europea. Consulte el registro de declaraciones de propiedades saludables.
Advertencias en Canadá
Cautions and Warnings : Warnings: Since drowsiness or visual impairment, disorientation, and confusion may occasionally occur with the use of scopolamine, patients should be cautioned about engaging in activities that require mental alertness, such as driving a motor vehicle or operating dangerous machinery. Potentially alarming idiosyncratic reactions may occur with ordinary therapeutic doses of scopolamine. In patients with a history of possible raised intraocular pressure (pressure pain, blurred vision, glaucomatous halo), TRANSDERM-V should be employed only after ophthalmologic examination excludes glaucoma. TRANSDERM-V should be discontinued if it causes blurring of vision with pressure pain within the eye. Care should be taken after removal of the system as side-effects may persist for up to 24 hours or longer. Due to the presence of aluminum in one of the layers of the system, the patch should be removed before medical scans. Precautions: TRANSDERM-V (scopolamine) should be used with caution in patients with dysuria, eg. due to urinary bladder neck obstruction. Caution should be exercised when administering an antiemetic or antimuscarinic drug to patients suspected of having intestinal obstruction, eg. pyloric stenosis. TRANSDERM-V should be used with caution in the elderly or in individuals with impaired metabolic, liver or kidney functions. In certain cases, especially in the elderly, confusional states and/or visual hallucinations may occur. Should this occur, TRANSDERM-V should be removed at once. If severe symptoms persist, appropriate countermeasures should be taken. In epileptic patients, isolated cases of increased seizure frequency have been reported. Use in Children: Children are particularly susceptible to the side effects of belladonna alkaloids. TRANSDERM-V should not be used in children because it is not known whether the amount of scopolamine released could product serious adverse effects in children. Pregnancy: TRANSDERM-V should be used during pregnancy only if the anticipated benefit justifies the potential risk to the mother and fetus. Lactation: TRANSDERM-V should not be administered to nursing mothers since scopolamine is excreted into breast milk. Consult a health care practitioner prior to use if you are pregnant or breastfeeding (due to lack of sufficient safety evidence for these subpopulations). Drug Interactions: TRANSDERM-V should be employed with caution in patients taking drugs which act on the CNS. This applies particularly to patients under treatment with drugs displaying anticholinergic properties, for example, belladonna alkaloids, antihistamines, antidepressants (tricyclics and MAO inhibitors), phenothiazines, amantadine and quinidine. Any parasympatholytic or sympathomimetic agent, or barbiturate should be administered with caution to persons wearing TRANSDERM-V. Patients should refrain from consuming alcohol while using TRANSDERM-V. Alcohol may interfere with the metabolism of the drug and could thus cause plasma levels to become elevated, which could intensify the side effects.
Texto original en inglés.
Fuente
Ficha oficial de Health Canada, licencia 80024336
Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias, consultado el 27 de octubre de 2026.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPSNH)
Texto original en francés.
Texto original en francés.
La fórmula vendida en Europa con el mismo nombre puede ser diferente. Esta información no sustituye el consejo de un médico o farmacéutico.
Lista en la revisión oficial del (registro: Base de datos de productos de salud natural autorizados (BDPSNH), Health Canada: productos autorizados, ingredientes, dosis, usos y advertencias).